Industry Spotlight  |
Digital Biomarkers & Digital Pathology

The Applications of Biomarkers in Digital Pathology and Personalised Medicine

Edited by Ben Norris |
12 October 2023
Digital pathology could enable the integration of biomarkers to enhance therapy effectiveness, potentially improving the capabilities of pathologists through AI-powered tools.

To be clinically relevant, biomarkers in digital pathology must be shown to be beneficial in therapies after they have been established as valid. 

Technological advances have facilitated the development of digital pathology-based approaches for qualitative pathologic assessments. 

The historical role of pathology in the drug development process could be augmented accordingly. 

In the context of biomarkers in digital pathology, the parameters must meet the definition of a biomarker as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention.

Digital pathology is being actively developed accordingly to mitigate issues posed by the increased volume and complexity of histopathological workflows. 

Many clinical workflows in oncology rely on predictive or prognostic molecular biomarkers, but the growing number of complex biomarkers – multidimensional health indicators observed together – ups the cost and time involved in decision-making. 

Opportunities for Biomarkers in Digital Pathology

At present, molecular biomarkers in oncology workflows can be prognostic or predictive, allowing for an adjustment of treatment intensity accordingly. 

As one example of an area of expansion for biomarkers in digital pathology, they can be applied to stage II colorectal cancer, where microsatellite instability (MSI) is a prognostic biomarker. 

If MSI is detected, a lower treatment intensity of adjuvant chemotherapy can be used since the treatment prognosis for these patients is typically much better. 

By contrast, predictive biomarkers enable a particular targeted treatment to be chosen for a specific patient group. 

Similarly, in the context of breast cancer, the detection of HER2 positivity makes patients eligible for treatment with anti-HER2 agents, acting as a strong predictive biomarker in this disease.

Integration of biomarkers in digital pathology for these approaches would help considerably for biomarker identification and analysis, with automated pathology workflows able to facilitate the detection, grading, and subtyping of tumour tissue in histology images. 

Future Applications and Predictions 

Despite the numerous advantages of biomarkers in digital pathology, the approach is not the easiest to adopt into clinical practice. 

It is necessary to prove whether diagnostic and classification algorithms using digital pathology are useful in clinical practices before they can be adopted. 

In years to come, the traditional role of pathologists in delivering accurate diagnoses or assessing biomarkers for companion diagnostics may be enhanced in precision, reproducibility, and scale through AI-powered tools. 

Get your weekly dose of industry news and announcements here, or head over to our Biomarkers portal to catch up with the latest advances in diagnostics. To learn more about our upcoming Precision Oncology Europe conference, visit our event website to download an agenda and register your interest.

How would you rate this content?

Share this article

Sign up for our monthly Biomarkers Newsletter

You may also be interested in...

Industry Spotlight
Digital biomarkers hold promise for healthcare, offering improved rare disease detection and cost reduction, with the potential for future implementation in clinical healthcare settings.
23 October 2023
Insight Article
While the integration of AI in digital pathology will require a concerted push from those in the industry, the ability to rapidly process large amounts of tissue data with a high degree of accuracy makes it a potentially invaluable resource for diseases which are highly heterogeneous.
24 March 2023

Continue browsing

Share this article

Join our Biomarkers mailing list

Stay up to date

Sign up for our monthly Editorial Newsletter to keep up with all things Biomarkers